6690
Early Detection and Personalized Treatment of Breast Cancer, Using Comparative Genomics
Tabach Yuval, HUJI, School of Medicine - IMRIC, Developmental Biology and Cancer Research
Prof. Levy-Lahad Ephrat – Director of the Medical Genetics Institute at Shaare Zedek Hospital, Jerusalem
Background
-
Breast cancer is the most common cancer among women.
-
In >70% of cases with suspected hereditary, no mutations could be found in the known susceptibility genes (BRCA1, BRCA2, PALB2, etc.).
-
Establishing a comprehensive panel that identifies the driver of mutations in patients is of particular importance for personalized risk assessment, prevention and treatment of breast cancer.
Our innovation
Using cutting-edge comparative genomics, data integration and machine learning, we developed a comprehensive gene panel that can identify an increased risk of breast cancer and offer personalized treatment options based on PARP inhibitors.
We aim to develop a platform for predicting the risk for hereditary breast cancer in significantly more patients and offer personalized drug treatment based on the identified mutations.
Application for use:
a. For Breast Cancer patients:
-
Identify the causative mutations Breast cancer patient
-
Optimize and guide treatments
b. for Woman at risk:
-
Risk predictor
-
Optimized treatments (PARPi)